About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01017640

Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

Study identifier: NCT01017640
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

  • Solid tumor for which no curative or standard therapy exists or is no longer effective, tumor demonstrates deficiency in the Fanconi anemia pathway
  • prior PARP inhibitor treatment allow if used as a single agent
  • Up to two chemotherapy regimens for metastatic disease are allowed; in addition, prior adjuvant/neo- adjuvant chemotherapy, hormonal therapy, molecular targeted therapy or Erb inhibitor treatments (e.g., erlotinib, herceptin, sorafenib, sunitinib) will be allowed and will not count towards eligibility

Type of study:

Phase I study

Treatment:

Participants assigned to one of two groups:

  • Oral veliparib daily
  • 28 day cycles with mitomycin C intravenously on day 1 and oral veliparib on either days 1-7, 1-14, 1-21, or 1-28

Study sites:

District of Columbia
District of Columbia
Lombardi Comprehensive Cancer Center at Georgetown University
Contact: John L. Marshall 202-687-6459 Mc183@georgetown.edu

Ohio
Columbus
Ohio State University Medical Center
Contact: Miguel A. Villalona-Calero 614-293-9424 miguel.villalona@osumc.edu

Page updated 06/14/13

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org